Does RAD 140 shrink balls? It can. RAD140 is a selective androgen receptor modulator (SARM), and it binds the androgen receptor, the protein that carries androgen signals inside cells. Those signals tell the pituitary gland beneath the brain to release less luteinising hormone (LH) and follicle-stimulating hormone (FSH), the two hormones that keep the testes working.
A published case report shows that route in a person. A man had been exposed to commercial supplements that held RAD140 together with undeclared testosterone, the main androgen of the testes. He developed hypogonadotropic hypogonadism, low testosterone caused by a weak pituitary signal, and once the exposure ended his hormone levels returned to normal. How often the testes shrink, and how fully they regain their size, is known only from descriptions outside the published studies. Changes in the testes are one part of the wider record of RAD 140 side effects.
The SARM RAD140 itself comes from breast-cancer research: it was characterised in cell and patient-derived xenograft models of androgen and oestrogen receptor-positive breast cancer, and those preclinical data supported its further clinical study in that disease. Nothing in that work looked at the testes. This article sets out what the published evidence and the descriptions outside it show about RAD140 and the testes, and where that evidence stops. Libido, erectile function, liver tissue and other organs have their own articles.
How RAD140 can turn down the testes’ hormone signal
RAD140 reaches the testes by a chain of command, because they do not run themselves. They take their orders from the hypothalamus and the pituitary gland, a chain of signals known as the hypothalamic-pituitary-gonadal (HPG) axis. The pituitary gland releases the hormones that stimulate the gonads, called gonadotropins: luteinising hormone (LH) tells the testes to make their own testosterone, and FSH supports spermatogenesis, the production of sperm within them. Androgens close the loop. When their level rises the hypothalamus and the pituitary release less: that control is called negative feedback, by which a hormone damps its own stimulus. RAD140 binds the androgen receptor, so to the axis it looks like more androgen, and the signal to the testes falls.
That is what happens with any exogenous androgen. A 2026 narrative review describes the same suppression in men after exposure to anabolic-androgenic steroids, together with the low-testosterone state that can persist once the exposure ends. In those men clomiphene citrate raises gonadotropin release and preserves spermatogenesis, which shows how far the testes depend on the pituitary signal. The review describes the axis, not RAD140 itself, because its men had been exposed to steroids rather than SARMs.
Anabolic steroid-induced hypogonadism (ASIH) is a disorder resulting from prolonged suppression of the hypothalamic-pituitary-gonadal axis, frequently observed in anabolic-androgenic steroid (AAS) users after cessation.
Could RAD140 spare the pituitary while acting on muscle? Vosilasarm, as the compound was named in clinical trials, has shown tissue selectivity, a difference in its receptor action from one tissue to another, only in cell models: it activated the androgen receptor in breast-cancer cells but not in prostate-cancer cells. Cell data of that kind cannot show that the pituitary gland is spared, and none of the studies this article draws on tested the point. The feedback route runs through the very receptor the compound targets, where it is a potent agonist.
What a case report recorded after products containing RAD140
The case is a man who developed hypogonadotropic hypogonadism, low testosterone caused by a weak pituitary signal, after 6 months of exposure to commercially sold supplements (the table below gives his age). With the hormone deficiency came bilateral gynaecomastia, the enlargement of male breast tissue. Analysis of the three supplements found RAD-140 together with cardarine and MK-677, a secretagogue that raises the pituitary output of growth hormone. The same products held three hormones that their labels did not declare: testosterone, growth hormone and oestradiol, the body’s main oestrogen.
A further steroid analysis turned up an unidentified compound eluting close to the testosterone peak. Even with that mixture inside him, the man’s symptoms resolved fully and his hormone results returned to normal once exposure to the supplements ended. The record is a single case (n=1) with mixed products, so the fall in hormones cannot be attributed to RAD140 alone. The other RAD140 case report among this article’s sources concerns idiosyncratic drug-induced liver injury in a younger man (the table also gives his age) and records nothing on the testes.
Two published RAD140 case reports
Case
Exposure
What was recorded
Outcome after stopping
Bearing on the testes
40-year-old man
Commercial gym supplements for 6 months, holding RAD-140, MK-677 and cardarine plus undeclared testosterone, oestradiol and growth hormone
Hypogonadotropic hypogonadism and bilateral gynaecomastia
Full resolution of symptoms; hormone results returned to normal
Pituitary signal and testosterone fell, but with mixed products; no testicular volume measured
Idiosyncratic drug-induced liver injury with jaundice
Liver function normalised at 2-month follow-up
Nothing recorded on the testes
How much do the testicles shrink on RAD140?
In descriptions beyond the trials, the loss of testicular size under RAD140 is modest to moderate rather than dramatic, and it follows the suppression of LH and FSH. Testicular atrophy, the shrinking of the testes through loss of tissue, scales with how far spermatogenesis slows. Most of the volume of a testis lies in the seminiferous tubules, the coiled ducts where sperm form, and those tubules depend on FSH and on the high concentration of testosterone inside the testis.
In those accounts the size of the reduction depends on how deep and how long the suppression of the HPG axis is, and on the starting volume of the testes. Controlled human data on RAD140 itself are scarce, so the view rests mainly on the wider evidence on androgen-induced suppression of the axis, and the published case summary gives no measurement of testicular volume.
How often does RAD140 cause testicular shrinkage?
Outside the trial record, testicular shrinkage linked to RAD140 is described as clear in some instances, slight or absent in others, and in a few confined to one side. Whether it happens at all, and how far it goes, are the two questions that recur most in those accounts, and they leave both open.
The same accounts explain the effect through the hormones: SARMs suppress LH and FSH and so lower the testes’ own testosterone output, the mechanism generally held to lie behind the effect of SARMs on testicle size. The suppression is described as deeper with greater exposure and longer duration, and more marked when other androgenic or suppressive compounds are present. Beyond exposure, individual variation in hormonal response is the usual explanation for why the change differs so much from one instance to the next.
How can a user tell shrinkage is happening, and is testicle pain a warning sign?
Outside the published trials, shrinkage under suppression of the HPG axis is described as a gradual loss of testicular volume, often with a softer, less firm consistency of the testes. Clinicians assess such a change with one of the first two methods below and usually add the last two:
comparison of the testes with an orchidometer, a set of graded beads of known volume
examination of the testes by scrotal ultrasound
blood tests for LH, FSH and testosterone
a semen analysis
Pain is a different matter. Outside the published trials, simple shrinkage from hormonal suppression is described as painless, so testicular pain, aching, swelling or a lump points to some other cause and calls for medical assessment. Sudden, severe testicular pain is treated in clinical medicine as an emergency, because conditions such as testicular torsion, the twisting of a testis on its spermatic cord, need urgent evaluation. None of the studies this article draws on examined those signs with RAD140 specifically.
Does shrinkage on RAD140 lower sperm count or fertility, and does that recover?
Outside the published trials, testicular shrinkage on exposure to RAD140 is described as going with a lower sperm count and with reduced fertility. The link is the axis again: testicular atrophy reflects suppression of the HPG axis, LH and FSH fall under exposure to SARMs, and with them falls the testosterone made inside the testes, which sustains spermatogenesis. That relation between testicular volume, sperm production and fertility is what connects RAD-140 and fertility.
In those accounts sperm production is likely to recover once exposure ends, because the HPG axis tends to restart and spermatogenesis can resume. The time to recovery varies widely, and after prolonged or profound suppression full recovery is not assured. For RAD140 itself, controlled human evidence on the point is very limited.
What happens to the hormones once exposure ends
In the one published case, the hormones returned to normal once exposure ended: the hypogonadotropic hypogonadism normalised after the supplements were withdrawn, and the gynaecomastia and the other symptoms resolved fully. One case says little about how predictable recovery from RAD-140 testosterone suppression is. The 2026 review reports that hormone recovery after androgen exposure varies between individuals and that no treatment for it has been standardised.
The review traces the low-testosterone state left after steroid exposure, known as anabolic steroid-induced hypogonadism (ASIH), to prolonged suppression of the HPG axis. Symptoms do not always follow the blood results: symptomatic recovery varies even where the hormone parameters improve. Measuring the recovery has its own difficulty. Immunoassays, the laboratory tests that measure hormones through antibody binding, have limited specificity, and mass spectrometry, which identifies molecules by their mass, is the more reliable way to judge hormonal recovery and to detect residual steroid metabolites. All of this comes from men after anabolic-androgenic steroid use, not from studies of the compound itself, so it frames the question for RAD140 without settling it.
Will the testicles go back to normal size after RAD140, and how long does it take?
Outside the published trials, the reduction in testicular size linked to RAD140 is described as reversible in most cases, with size returning gradually over weeks to months after exposure ends. The return follows the recovery of the hormones the compound suppresses, LH, FSH and the testosterone made by the testes themselves. Testosterone levels come back first in those accounts, while spermatogenesis and full testicular volume take longer, and recovery is slower with longer exposure, older age and weaker testicular function before exposure, and incomplete in a minority of cases.
Among the effects described outside the trials, a reduction that persists after exposure has ended is a frequent one, and with it comes doubt over whether full size ever returns; how long the return takes is a recurring uncertainty. One detail recurs as well: a higher, drawn-up position of the testes, like their position under a surge of adrenaline.
Can clomiphene, enclomiphene or hCG help the testes recover?
In clinical studies of men after exposure to anabolic-androgenic steroids, clomiphene citrate consistently improves the hormonal parameters, though symptoms recover less predictably, and the 2026 review names it the most commonly used off-label medication in such men. It is a selective oestrogen receptor modulator (SERM), a drug that blocks or mimics the action of oestrogen depending on the tissue. Blocking oestrogen receptors in the hypothalamus and pituitary removes part of the negative feedback, so gonadotropin secretion rises, the testes make more of their own testosterone and spermatogenesis is preserved.
[Figure 1. Clomiphene’s route through the hormone axis. Clomiphene blocks oestrogen receptors. This lowers negative feedback on the hypothalamus and pituitary, so LH, FSH and testosterone rise. The 2026 review describes men after anabolic steroids. It studied no SARM, RAD140 included. Symptomatic recovery varied, and no treatment is standardised.]
The review also discusses human chorionic gonadotropin (hCG), a hormone that stimulates the testes as LH does, and aromatase inhibitors, drugs that block the conversion of androgens to oestrogens. Outside the published studies, both figure in descriptions of RAD 140 PCT, the recovery of the hormone axis after the compound. Concerns remain over the long-term efficacy of clomiphene and its adverse metabolic effects, and among newer approaches the review names enclomiphene citrate, the trans isomer of clomiphene citrate, as an emerging option not yet validated in men with ASIH.
All of this describes men after anabolic-androgenic steroids. The review examined no SARM, and none of the studies this article draws on has tested these drugs after exposure to RAD 140. What the review shows is how the testes respond when the pituitary signal is restored, not how they recover from a SARM.
Recovery options in the 2026 review
Option
What it is
What the review reports
Tested after RAD140?
Clomiphene citrate
SERM that reduces negative feedback on the hypothalamus and pituitary
Most commonly used off-label; consistently improves hormonal parameters; symptomatic recovery varies; concerns over metabolic effects and long-term efficacy
No; review covers men after anabolic steroids
hCG
Hormone that stimulates the testes as LH does
Used in unsupervised post-cycle therapy
No
Aromatase inhibitors
Drugs that block conversion of androgens to oestrogens
Used in unsupervised post-cycle therapy
No
Enclomiphene
Trans isomer of clomiphene citrate
Emerging option, not yet validated in men with ASIH
No
What the products behind these reports contained
The products in the case report held RAD140, MK-677 and cardarine, together with testosterone, oestradiol and growth hormone that their labels did not declare. A further analysis by liquid chromatography mass spectrometry (LC-MS), a method that separates the compounds of a sample and identifies each by its mass, found an unidentified compound eluting close to the testosterone peak. Undeclared testosterone suppresses the HPG axis on its own, as anabolic-androgenic steroids do, so a fall in hormone levels after such products cannot be read as an effect of the SARM alone.
The Therapeutic Goods Administration (TGA), which regulates medicines in Australia, found the opposite fault: its testing showed unapproved SARM products significantly under-dosed. That concerns the amount of the SARM rather than any added substance, and it matters because the suppression of LH and FSH is generally linked to the dose and duration of exposure. The two faults pull in opposite directions, undeclared testosterone deepening the suppression and under-dosing making it shallower. How far the TGA’s finding reaches for RAD140 quality elsewhere is not known, because the TGA tested products in Australia.
Neither a label nor a stated amount, then, shows the exposure a product produced. A change in testicular size or hormone levels after such a product cannot be traced to a known exposure, and labelled amounts offer no check on the link between greater exposure and deeper suppression. Batch and purity data matter most where products hold undisclosed hormones or less than their labels state; they accompany the RAD140 (Testolone) we supply for laboratory research, and the rest of our range of UK SARMs.
What the tested products actually contained
Finding
What was found
Where tested
Source
Banned compounds present
RAD-140, MK-677 and cardarine in all 3 supplements
Supplements from one case report
Undeclared hormones
Testosterone, oestradiol and growth hormone in all 3 supplements, none on the labels
Supplements from one case report
Unidentified substance
Compound eluting close to the testosterone peak on LC-MS
The hormone evidence that bears on testolone rests on one published case, and the products in that case also held undisclosed hormones. The recovery data come from men after anabolic-androgenic steroids, not after SARMs. Regulatory testing showed that products sold as SARMs may not hold what their labels state. And the descriptions outside the published studies show which questions recur, not what the answers are, because none of them is a measurement.
So only descriptions outside the trials speak to how often RAD140 shrinks the balls and to whether testicular size returns after exposure ends. No published study among this article’s sources has measured the frequency of that shrinkage or the return of testicular size.
What each source shows on the testes
Source
Design and population
What it shows
What it cannot show
Chong et al. 2024
Case report with product analysis, n=1
Hypogonadotropic hypogonadism that normalised after stopping mixed supplements
An effect of RAD140 alone; testicular size
Ladna et al. 2023
Case report, one 26-year-old man
Liver injury linked to RAD140
Any effect on the testes
Yu et al. 2017
Preclinical, breast-cancer cell and xenograft models
RAD140 binds the androgen receptor with high affinity and acts as a potent agonist
Whether the human pituitary or testes are affected
Bandura et al. 2026
Narrative review, men after anabolic steroid use
Hormone recovery after androgens varies; no standard treatment
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
According to the article, how can RAD140 lead to smaller testes?
It blocks the androgen receptor inside the testicular tissue
Its androgen feedback lowers pituitary release of LH and FSH ✓
It is converted to oestradiol, which acts on the testes
It damages the testes directly, much as it injures the liver
RAD140 activates the androgen receptor, and androgen feedback leads the pituitary to release less LH and FSH, the hormones that drive the testes.
Why can the hormone fall in the published case not be attributed to RAD140 alone?
The man's testosterone was already low before his exposure
His hormones were measured only by low-specificity immunoassays
The products also held testosterone missing from their labels ✓
He had also been treated with clomiphene during his exposure
The supplements also held testosterone, oestradiol and growth hormone that their labels did not declare, so the effect of RAD140 cannot be separated out.
What happened to the man's hormone levels once he stopped the supplements?
They recovered only after treatment with clomiphene citrate
They stayed low, leaving lasting steroid-induced hypogonadism
They partly recovered, while the gynaecomastia persisted
They returned to normal, and his symptoms resolved fully ✓
Once the supplements were withdrawn, his hypogonadotropic hypogonadism normalised and his symptoms, including the gynaecomastia, resolved fully.
What have the published studies cited in the article measured about testicular size on RAD140?
No study measured how often it shrinks or whether it returns ✓
A trial found size returned within weeks of stopping exposure
The case report recorded a loss of volume on scrotal ultrasound
Cell models showed shrinkage that scaled with exposure
The one hormone case recorded no testicular volume, and none of the sources measured how often shrinkage occurs or whether size returns.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Postdoctoral Clinical Research Fellow; Specialty Registrar in Endocrinology and Diabetes
Bonnie Grant is a postdoctoral clinical research fellow and a specialty registrar in endocrinology and diabetes in the Department of Metabolism, Digestion and Reproduction at Imperial College London. Bonnie specialises in reproductive medicine and fertility.
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
Does RAD 140 shrink balls? Hormone suppression and recovery
By Elizabeth Hyams · Reviewed by Bonnie Grant, MBBS
Published · Updated · 16 min read
RAD140 and testicle size: the short answer
Does RAD 140 shrink balls? It can. RAD140 is a selective androgen receptor modulator (SARM), and it binds the androgen receptor, the protein that carries androgen signals inside cells. Those signals tell the pituitary gland beneath the brain to release less luteinising hormone (LH) and follicle-stimulating hormone (FSH), the two hormones that keep the testes working.
A published case report shows that route in a person. A man had been exposed to commercial supplements that held RAD140 together with undeclared testosterone, the main androgen of the testes. He developed hypogonadotropic hypogonadism, low testosterone caused by a weak pituitary signal, and once the exposure ended his hormone levels returned to normal. How often the testes shrink, and how fully they regain their size, is known only from descriptions outside the published studies. Changes in the testes are one part of the wider record of RAD 140 side effects.
The SARM RAD140 itself comes from breast-cancer research: it was characterised in cell and patient-derived xenograft models of androgen and oestrogen receptor-positive breast cancer, and those preclinical data supported its further clinical study in that disease. Nothing in that work looked at the testes. This article sets out what the published evidence and the descriptions outside it show about RAD140 and the testes, and where that evidence stops. Libido, erectile function, liver tissue and other organs have their own articles.
How RAD140 can turn down the testes’ hormone signal
RAD140 reaches the testes by a chain of command, because they do not run themselves. They take their orders from the hypothalamus and the pituitary gland, a chain of signals known as the hypothalamic-pituitary-gonadal (HPG) axis. The pituitary gland releases the hormones that stimulate the gonads, called gonadotropins: luteinising hormone (LH) tells the testes to make their own testosterone, and FSH supports spermatogenesis, the production of sperm within them. Androgens close the loop. When their level rises the hypothalamus and the pituitary release less: that control is called negative feedback, by which a hormone damps its own stimulus. RAD140 binds the androgen receptor, so to the axis it looks like more androgen, and the signal to the testes falls.
That is what happens with any exogenous androgen. A 2026 narrative review describes the same suppression in men after exposure to anabolic-androgenic steroids, together with the low-testosterone state that can persist once the exposure ends. In those men clomiphene citrate raises gonadotropin release and preserves spermatogenesis, which shows how far the testes depend on the pituitary signal. The review describes the axis, not RAD140 itself, because its men had been exposed to steroids rather than SARMs.
Could RAD140 spare the pituitary while acting on muscle? Vosilasarm, as the compound was named in clinical trials, has shown tissue selectivity, a difference in its receptor action from one tissue to another, only in cell models: it activated the androgen receptor in breast-cancer cells but not in prostate-cancer cells. Cell data of that kind cannot show that the pituitary gland is spared, and none of the studies this article draws on tested the point. The feedback route runs through the very receptor the compound targets, where it is a potent agonist.
What a case report recorded after products containing RAD140
The case is a man who developed hypogonadotropic hypogonadism, low testosterone caused by a weak pituitary signal, after 6 months of exposure to commercially sold supplements (the table below gives his age). With the hormone deficiency came bilateral gynaecomastia, the enlargement of male breast tissue. Analysis of the three supplements found RAD-140 together with cardarine and MK-677, a secretagogue that raises the pituitary output of growth hormone. The same products held three hormones that their labels did not declare: testosterone, growth hormone and oestradiol, the body’s main oestrogen.
A further steroid analysis turned up an unidentified compound eluting close to the testosterone peak. Even with that mixture inside him, the man’s symptoms resolved fully and his hormone results returned to normal once exposure to the supplements ended. The record is a single case (n=1) with mixed products, so the fall in hormones cannot be attributed to RAD140 alone. The other RAD140 case report among this article’s sources concerns idiosyncratic drug-induced liver injury in a younger man (the table also gives his age) and records nothing on the testes.
Two published RAD140 case reports
How much do the testicles shrink on RAD140?
In descriptions beyond the trials, the loss of testicular size under RAD140 is modest to moderate rather than dramatic, and it follows the suppression of LH and FSH. Testicular atrophy, the shrinking of the testes through loss of tissue, scales with how far spermatogenesis slows. Most of the volume of a testis lies in the seminiferous tubules, the coiled ducts where sperm form, and those tubules depend on FSH and on the high concentration of testosterone inside the testis.
In those accounts the size of the reduction depends on how deep and how long the suppression of the HPG axis is, and on the starting volume of the testes. Controlled human data on RAD140 itself are scarce, so the view rests mainly on the wider evidence on androgen-induced suppression of the axis, and the published case summary gives no measurement of testicular volume.
How often does RAD140 cause testicular shrinkage?
Outside the trial record, testicular shrinkage linked to RAD140 is described as clear in some instances, slight or absent in others, and in a few confined to one side. Whether it happens at all, and how far it goes, are the two questions that recur most in those accounts, and they leave both open.
The same accounts explain the effect through the hormones: SARMs suppress LH and FSH and so lower the testes’ own testosterone output, the mechanism generally held to lie behind the effect of SARMs on testicle size. The suppression is described as deeper with greater exposure and longer duration, and more marked when other androgenic or suppressive compounds are present. Beyond exposure, individual variation in hormonal response is the usual explanation for why the change differs so much from one instance to the next.
How can a user tell shrinkage is happening, and is testicle pain a warning sign?
Outside the published trials, shrinkage under suppression of the HPG axis is described as a gradual loss of testicular volume, often with a softer, less firm consistency of the testes. Clinicians assess such a change with one of the first two methods below and usually add the last two:
Pain is a different matter. Outside the published trials, simple shrinkage from hormonal suppression is described as painless, so testicular pain, aching, swelling or a lump points to some other cause and calls for medical assessment. Sudden, severe testicular pain is treated in clinical medicine as an emergency, because conditions such as testicular torsion, the twisting of a testis on its spermatic cord, need urgent evaluation. None of the studies this article draws on examined those signs with RAD140 specifically.
Does shrinkage on RAD140 lower sperm count or fertility, and does that recover?
Outside the published trials, testicular shrinkage on exposure to RAD140 is described as going with a lower sperm count and with reduced fertility. The link is the axis again: testicular atrophy reflects suppression of the HPG axis, LH and FSH fall under exposure to SARMs, and with them falls the testosterone made inside the testes, which sustains spermatogenesis. That relation between testicular volume, sperm production and fertility is what connects RAD-140 and fertility.
In those accounts sperm production is likely to recover once exposure ends, because the HPG axis tends to restart and spermatogenesis can resume. The time to recovery varies widely, and after prolonged or profound suppression full recovery is not assured. For RAD140 itself, controlled human evidence on the point is very limited.
What happens to the hormones once exposure ends
In the one published case, the hormones returned to normal once exposure ended: the hypogonadotropic hypogonadism normalised after the supplements were withdrawn, and the gynaecomastia and the other symptoms resolved fully. One case says little about how predictable recovery from RAD-140 testosterone suppression is. The 2026 review reports that hormone recovery after androgen exposure varies between individuals and that no treatment for it has been standardised.
The review traces the low-testosterone state left after steroid exposure, known as anabolic steroid-induced hypogonadism (ASIH), to prolonged suppression of the HPG axis. Symptoms do not always follow the blood results: symptomatic recovery varies even where the hormone parameters improve. Measuring the recovery has its own difficulty. Immunoassays, the laboratory tests that measure hormones through antibody binding, have limited specificity, and mass spectrometry, which identifies molecules by their mass, is the more reliable way to judge hormonal recovery and to detect residual steroid metabolites. All of this comes from men after anabolic-androgenic steroid use, not from studies of the compound itself, so it frames the question for RAD140 without settling it.
Will the testicles go back to normal size after RAD140, and how long does it take?
Outside the published trials, the reduction in testicular size linked to RAD140 is described as reversible in most cases, with size returning gradually over weeks to months after exposure ends. The return follows the recovery of the hormones the compound suppresses, LH, FSH and the testosterone made by the testes themselves. Testosterone levels come back first in those accounts, while spermatogenesis and full testicular volume take longer, and recovery is slower with longer exposure, older age and weaker testicular function before exposure, and incomplete in a minority of cases.
Among the effects described outside the trials, a reduction that persists after exposure has ended is a frequent one, and with it comes doubt over whether full size ever returns; how long the return takes is a recurring uncertainty. One detail recurs as well: a higher, drawn-up position of the testes, like their position under a surge of adrenaline.
Can clomiphene, enclomiphene or hCG help the testes recover?
In clinical studies of men after exposure to anabolic-androgenic steroids, clomiphene citrate consistently improves the hormonal parameters, though symptoms recover less predictably, and the 2026 review names it the most commonly used off-label medication in such men. It is a selective oestrogen receptor modulator (SERM), a drug that blocks or mimics the action of oestrogen depending on the tissue. Blocking oestrogen receptors in the hypothalamus and pituitary removes part of the negative feedback, so gonadotropin secretion rises, the testes make more of their own testosterone and spermatogenesis is preserved.
The review also discusses human chorionic gonadotropin (hCG), a hormone that stimulates the testes as LH does, and aromatase inhibitors, drugs that block the conversion of androgens to oestrogens. Outside the published studies, both figure in descriptions of RAD 140 PCT, the recovery of the hormone axis after the compound. Concerns remain over the long-term efficacy of clomiphene and its adverse metabolic effects, and among newer approaches the review names enclomiphene citrate, the trans isomer of clomiphene citrate, as an emerging option not yet validated in men with ASIH.
All of this describes men after anabolic-androgenic steroids. The review examined no SARM, and none of the studies this article draws on has tested these drugs after exposure to RAD 140. What the review shows is how the testes respond when the pituitary signal is restored, not how they recover from a SARM.
Recovery options in the 2026 review
What the products behind these reports contained
The products in the case report held RAD140, MK-677 and cardarine, together with testosterone, oestradiol and growth hormone that their labels did not declare. A further analysis by liquid chromatography mass spectrometry (LC-MS), a method that separates the compounds of a sample and identifies each by its mass, found an unidentified compound eluting close to the testosterone peak. Undeclared testosterone suppresses the HPG axis on its own, as anabolic-androgenic steroids do, so a fall in hormone levels after such products cannot be read as an effect of the SARM alone.
The Therapeutic Goods Administration (TGA), which regulates medicines in Australia, found the opposite fault: its testing showed unapproved SARM products significantly under-dosed. That concerns the amount of the SARM rather than any added substance, and it matters because the suppression of LH and FSH is generally linked to the dose and duration of exposure. The two faults pull in opposite directions, undeclared testosterone deepening the suppression and under-dosing making it shallower. How far the TGA’s finding reaches for RAD140 quality elsewhere is not known, because the TGA tested products in Australia.
Neither a label nor a stated amount, then, shows the exposure a product produced. A change in testicular size or hormone levels after such a product cannot be traced to a known exposure, and labelled amounts offer no check on the link between greater exposure and deeper suppression. Batch and purity data matter most where products hold undisclosed hormones or less than their labels state; they accompany the RAD140 (Testolone) we supply for laboratory research, and the rest of our range of UK SARMs.
What the tested products actually contained
Where the evidence on RAD140 and the testes stops
The hormone evidence that bears on testolone rests on one published case, and the products in that case also held undisclosed hormones. The recovery data come from men after anabolic-androgenic steroids, not after SARMs. Regulatory testing showed that products sold as SARMs may not hold what their labels state. And the descriptions outside the published studies show which questions recur, not what the answers are, because none of them is a measurement.
So only descriptions outside the trials speak to how often RAD140 shrinks the balls and to whether testicular size returns after exposure ends. No published study among this article’s sources has measured the frequency of that shrinkage or the return of testicular size.
What each source shows on the testes
Check what you remember
4 questions on this article; the right answer is marked.
RAD140 activates the androgen receptor, and androgen feedback leads the pituitary to release less LH and FSH, the hormones that drive the testes.
The supplements also held testosterone, oestradiol and growth hormone that their labels did not declare, so the effect of RAD140 cannot be separated out.
Once the supplements were withdrawn, his hypogonadotropic hypogonadism normalised and his symptoms, including the gynaecomastia, resolved fully.
The one hormone case recorded no testicular volume, and none of the sources measured how often shrinkage occurs or whether size returns.
Elizabeth Hyams · Imperial College London
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Bonnie Grant, MBBS · Imperial College London · Last reviewed
Postdoctoral Clinical Research Fellow; Specialty Registrar in Endocrinology and Diabetes
Bonnie Grant is a postdoctoral clinical research fellow and a specialty registrar in endocrinology and diabetes in the Department of Metabolism, Digestion and Reproduction at Imperial College London. Bonnie specialises in reproductive medicine and fertility.
Related Posts
Does RAD 140 increase libido? Erections and the evidence
Does RAD 140 increase libido: accounts describe an early rise then a fall, and a case report links RAD140 supplements to suppressed testosterone.
Is RAD140 liver toxic? What trials and case reports show
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
RAD 140 blood work: the markers and what the evidence shows
RAD 140 blood work centres on liver enzymes, bilirubin and SHBG, the markers its one human trial in breast cancer recorded rising or falling.
Is RAD-140 bad for kidneys? What the case reports show
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.